Alcidion (ASX:ALC) has acquired ExtraMed
Alcidion (ASX:ALC) has acquired ExtraMed Ltd., a UK provider of patient flow management software that helps address key pain-points for hospital administrative staff.
Alcidion is transforming healthcare with smart, intuitive and complementary software products and services that create a unique offering in the global healthcare market. It offers solutions that support interoperability, allow communication and task management, and deliver clinical decision support at the point-of-care to improve patient systems. Alcidion has delivered strong organic growth in FY20 (with solid revenue up 33% as of Q3). The acquisition of ExtraMed will further accelerate this growth profile. This will add nine NHS trusts (six being new to Alcidion), expanding its NHS presence to 27 trusts or ~19% of target Acute NHS market, with upside revenue potential on cross-sell opportunities for Miya (its flagship product).
ExtraMed is a long-standing UK market leader in patient flow and has a 20-year track record. It specializes in providing NHS trusts with software that helps frontline staff make informed decisions based on real-time visibility of patient flow.
Oaklins’ team in Australia acted as corporate advisor to the buyer in this transaction.
Talk to the deal team
Related deals
Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn moreEuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
Learn moreOlyos Group has acquired a controlling stake in NewScience
Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.
Learn more